News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novo Nordisk A/S (NVO)' Sales Assault on U.S. Diabetes Market Sets Rivalry


9/11/2013 7:46:58 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Drugmakers led by Novo Nordisk A/S (NOVOB) and Merck & Co. (MRK) are increasing sales efforts for their top-selling diabetes drugs to grab as much of the market as possible ahead of a wave of new therapies. At the start of this year, Novo, the world’s biggest maker of insulin, directed its sales force to boost promotion of the company’s drug Victoza. Soon after, revenue slowed for competing treatments from Merck and Bristol-Myers Squibb Co. (BMY), forcing those companies to put more resources behind their medicines and overhaul their strategies.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg


comments powered by Disqus
Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES